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In patients suﬀering from chronic hepatitis C, Interferon (INF) associated with ribavirin therapy can induce various side
eﬀects involving the skin. Our case describes the clinical course of a patient with chronic hepatitis C treated with pegylated
a2 INF plus ribavirin. After 6 weeks of therapy he developed psoriasis. However, given the progressive improvement of his trans-
aminase levels and viral load decrease, we continued the protocol of the treatment and we started topical calcipotriol/betametha-
sone dipropionate ointment for psoriasic lesions. After this, the psoriasis improved in a slow but comprehensive manner. This
paper suggests that physicians should keep in mind the possibility of the onset of psoriasis as a side eﬀect of INF treatment
for chronic hepatitis C.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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INF is an immune modulating agent, it is considered
the ﬁrst-line treatment of chronic hepatitis C in combi-
nation with ribavirin (Alberti and Benvegnu`, 2003). It
is known that INF-alfa can exacerbate pre-existing pso-
riasis, but new onset psoriasis has rarely been observed.
Herein, we present the case of a patient with chronic
hepatitis C who was treated with pegylated INF-alfa
and ribavirin, and developed psoriasis for the ﬁrst
time.http://dx.doi.org/10.1016/j.jdds.2015.01.002
2352-2410/ 2015 The Authors. Production and hosting by Elsevier B.V. on
This is an open access article under the CC BY-NC-ND license (http://creative
⇑ Corresponding author.
Peer review under responsibility of King Saud University.2. Case report
A 66-year-old male was followed in our department for
hepatitis C, HCV-RNA was positive, the genotype was
characterized as 2i with Metavir score A2 F2. His treat-
ment protocol was consisting of pegylated INF alfa-2a
180 lg injected subcutaneously once a week and ribavirin
800 mg daily. He suﬀered from typical self-limited ﬂu-like
syndrome, with fever, arthromyalgias and asthenia which
usually last for two days. He developed after 6 weeks of
treatment erythematous scaly plaques. He had no previous
history of cutaneous disease such as psoriasis and he did
not take others medicaments that can induce psoriasis.
He presented with sharply circumscribed erythematous pla-
ques with psoriatic scales on his trunk, elbows, extremities,
scalp and face (Fig. 1), with Flexural psoriasis lesions of the
underarms, groin, intergluteal fold and umbilicus. Lesions
were erythematous with well-deﬁned borders, bright,
slightly inﬁltrated and with little scaling (Fig. 2). The skinbehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
Figure 1. Multiple sharply demarcated erythematous and scaly plaques on the extremities (A) scalp (B) elbow (C, D), face and ear (E).
Figure 2. Flexural psoriasis lesions of the umbilicus (A), folds of the groin (B).
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13% of his body surface area, methodical scraping of brocq
was positive with PASI score at 11, 7, SKINDEX at 32.
There were no nail changes. According to clinical ﬁndings,
the patient was diagnosed as having psoriasis. Before start-
ing pegylated INF alfa-2a and ribavirin, aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
levels were 120 and 105 U/L respectively, the platelet count
was 179,000/mm3 and hemoglobin 13.2 g/Dl. While receiv-
ing treatment, his transaminase and hepatitis C virus RNA
levels decreased, thyroid function test was normal. Unfor-
tunately, he developed thrombocytopenia (15,000/mm3)
and neutropenia (550/mm3). Skin biopsy has not been done
given the severe thrombocytopenia. The patient received a
transfusion of platelet pellet and injection of Granulocyte-
Colony Stimulating Factor, we stopped the treatment for a
week, and there was an increase in platelet (61,000/mm3)
and neutrophils (3270/mm). We did not notice a worsening
of psoriasis lesions after administration of Granulocyte-
Colony Stimulating Factor. We continued the INF treat-
ment due to a progressive reduction in transaminase levelsand the absence of any uncomfortable symptoms associat-
ed with the skin lesions. We started topical calcipotriol/be-
tamethasone dipropionate ointment. Subsequently, the
psoriasis slowly improved. The control after 4 weeks
showed unclogging of the lesions with a PASI at 5. The
patient was still under treatment.
3. Discussion
The current standard treatment for chronic hepatitis C
is a combination of pegylated INF-alfa and the antiviral
drug ribavirin, which are administered for 24 or 48 weeks
according to the genotype of the hepatitis C virus
(Alberti and Benvegnu`, 2003). The cutaneous adverse
eﬀects of pegylated and conventional INF have been
reported to be similar, including alopecia, urticaria, dry-
ness, pruritus, vasculitis, cutaneous necrosis and eczema
at injection sites (Manns et al., 2001). INF-alfa may both
exacerbate psoriasis and rarely induce it. Skin involvement
is highly variable among patients. Psoriasis induced by
INF can also aﬀect nails, the scalp, mucous and the joints.
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This is estimated to occur in 2–6% of patients with psoriasis
and has not been reported previously secondarily to the
administration of pegylated INF-alfa and ribavirin. In
1993, Garcia-Lora et al. (1993) ﬁrst described a case of pso-
riasis in a patient receiving INF alfa for chronic hepatitis.
A review of literature indicates that after the initiation of
INF treatment, the onset of psoriasis may range from
1 week to 16 months. With regard to the development of
the disease, new onset psoriasis takes longer to emerge that
the aggravation of pre-existing disease. Our case is the third
to report on a patient treated with pegylated INF alfa-2a
and ribavirin. The review of the three cases notices that
the average age for the onset of psoriasis was 52 years.
The eruption occurred 5 months after the institution of
therapy in one case (Gun-Wook Kim et al., 2013), and
after 16 months in the other case (Chong, 2011). In our
case the symptoms appeared precociously after 6 weeks.
Associated treatment with pegylated INF and speciﬁc
antivirals signiﬁcantly improved the prognosis of chronic
hepatitis C and B (Simin et al., 2007). Although, these
drugs tend to be myelotoxic causing hematological abnor-
malities, namely neutropenia and thrombocytopenia
neutropenia less than 500 neutrophils/ml occurred in
approximately 1% of patients treated with IFN and ribavir-
in and 2% of patients treated with IFN alone (Davis et al.,
1998; McHutchison et al., 1998; Poynard et al., 1998).
Human recombinant granulocyte colony-stimulating fac-
tors which are extensively administered in order to correct
neutropenia induced by antiviral therapy, may also be
involved in prompting or exacerbating cutaneous psoriasis
and its systemic complications. Development of psoriasi-
form skin lesions has been reported after administration
of granulocyte colony-stimulating factor (Sabbatani and
Manfredi, 2010). It may cause a lymphocytic dermatitis
that, similar to psoriasis, is characterized by a pro-inﬂam-
matory Th1-type cytokine (Mo¨ssner et al., 2004).
The available treatment options for psoriasis in hepatitis
patients are limited because common treatments such as
methotrexate and Oral retinoids are contraindicated due
to hepatotoxicity. Clobetasol dipropionate 0.05% ointment
or cream has been suggested as a cost-eﬀective choice. NB-
UVB therapy can be used. Calcipotriol avoids the potential
side eﬀect of corticosteroid atrophy and may be com-
pounded with clobetasol for additional eﬀect. Many clini-
cians believe that the onset of psoriasis during INF
therapy is an absolute contraindication to its continuation
(Citro et al., 2007). Afshar identiﬁed 32 publications
describing 36 subjects who developed a psoriatic eruption
while receiving IFN-alfa therapy for hepatitis C. Topical
therapies were a commonly employed treatment modality,
but led to resolution in only 30% of cases in which they
were employed solely. Cessation of IFN-alfa therapy led
to resolution in 93% of cases (Afshar et al., 2013).
Several mechanisms have been proposed to clarify the
close relationship between INF treatment and the induc-
tion of psoriasis. INF induced activation and maturationof T cells, which proliferate and migrate into the epidermis,
are a key step in the pathogenesis of psoriasis (Conrad
et al., 2007). Alternatively, because INF acts to increase
the lymphocytotoxic activity of natural killer lymphocytes
and induces keratinocytes to produce interleukin-1, it
may trigger and initiate the psoriatic process (Funk et al.,
1991). On the other hand, not all psoriasis patients develop
INF-alfa induced exacerbation, which probably reﬂects the
heterogeneity in the pathogenesis (Downs and Dunnill,
2000). The nature of the medication accounts for only part
of the development of a drug eruption, age, sex, immune
status and genetic make-up of the individual strongly deter-
mine the risk for the development of an adverse reaction to
a medication. Ribavirin could also stimulate Th1 responses
in T cells in vitro (Tam et al., 1999). However, no case of
psoriasis has been reported after treatment with ribavirin
alone.
All studies that have assessed the quality of life in chronic
hepatitis C showed that patients had an altered perception
of well-being (Foster et al., 1998). Side eﬀects of IFN and
ribavirin can also lead to a signiﬁcant impairment of quality
of life, especially when it reaches the skin; and may even
jeopardize the continuation of treatment. In our case the
SKINDEX was at 32. So these adverse eﬀects must be sys-
tematically sought (Gournay, 2002).
4. Conclusion
Psoriasis induced by pegylated INF alfa-2a and ribavir-
in for chronic hepatitis C is more and more recognized.
Early diagnosis leads to a better outcome; therefore, it is
important to be aware of this cutaneous adverse eﬀect
and to manage it.
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